期刊
JOURNAL OF SURGICAL ONCOLOGY
卷 119, 期 5, 页码 564-582出版社
WILEY
DOI: 10.1002/jso.25421
关键词
biomarkers; chemotherapy; colorectal cancer; immunotherapy; targeted therapy
The treatment of metastatic colorectal cancer has evolved over the last two decades with the FDA approval of several cytotoxic, biological, and targeted agents. In this paper, we review the impact of sidedness, RAS, BRAF, HER-2, and other immune biomarkers on metastatic colorectal cancer treatment selection and sequencing in both the palliative and curative intent settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据